Survivin-targeting anti-tumor agents and uses thereof

Abstract

Methods for treating various cancers by administering one or more compounds that target the dimeric protein survivin are disclosed. Pharmaceutical compositions containing such compounds are also disclosed, along with general methods of identifying anti-cancer compounds that target oncogenic dimeric proteins. Exemplary compounds that can be used in the disclosed methods of treatment and pharmaceutical compositions have the chemical structure:

1 .- 26 . (canceled) 
     
     
         27 . A method of treating cancer, the method comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising a survivin-targeting compound having the chemical structure 
       
         
           
           
               
               
           
         
         or is a pharmaceutically acceptable salt thereof, whereby the cancer is treated in the subject. 
       
     
     
         28 . The method of  claim 27  where the composition is administered to the subject by a route selected from the group consisting of orally, topically, nasally, parenterally, paracancerally, transmucosally, transdermally, intramuscularly, intravenously, intradermally, subcutaneously, intraperitoneally, intraventricularly, intracranially, intratumorally, or pulmonary delivery. 
     
     
         29 . The method of  claim 27  where the cancer treated is selected from the group consisting of breast cancer, colon cancer, lung cancer, pancreatic cancer, prostate cancer, ovarian cancer, and leukemia. 
     
     
         30 . The method of  claim 29  where the cancer treated is prostate cancer. 
     
     
         31 . A pharmaceutical composition comprising a survivin-targeting compound having the chemical structure 
       
         
           
           
               
               
           
         
         or is a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
       
     
     
         32 . A survivin-targeting compound for use in treating cancer in a subject, where the survivin-targeting compound has the chemical structure 
       
         
           
           
               
               
           
         
         or is a pharmaceutically acceptable salt thereof. 
       
     
     
         33 . The survivin-targeting compound of  claim 32  where the compound is for use in treating cancer that is selected from the group consisting of breast cancer, colon cancer, lung cancer, pancreatic cancer, prostate cancer, ovarian cancer, and leukemia. 
     
     
         34 . The survivin-targeting compound of  claim 32  where the compound is for use in treating prostate cancer. 
     
     
         35 . The survivin-targeting compound of  claim 32  where the compound is administered to the subject by a route selected from the group consisting of orally, topically, nasally, parenterally, paracancerally, transmucosally, transdermally, intramuscularly, intravenously, intradermally, subcutaneously, intraperitoneally, intraventricularly, intracranially, intratumorally, and pulmonary delivery. 
     
     
         36 . A survivin-targeting compound for use in manufacturing a medicament for treating cancer in a subject, where the survivin-targeting compound has the chemical structure 
       
         
           
           
               
               
           
         
         or is a pharmaceutically acceptable salt thereof. 
       
     
     
         37 . The survivin-targeting compound of  claim 36  where the medicament is for treating a cancer selected from the group consisting of breast cancer, colon cancer, lung cancer, pancreatic cancer, prostate cancer, ovarian cancer, and leukemia. 
     
     
         38 . The survivin-targeting compound of  claim 37 , where the medicament is for treating prostate cancer. 
     
     
         39 . The survivin-targeting compound of  claim 36  where the medicament is designed to be administered to the subject by a route selected from the group consisting of orally, topically, nasally, parenterally, paracancerally, transmucosally, transdermally, intramuscularly, intravenously, intradermally, subcutaneously, intraperitoneally, intraventricularly, intracranially, intratumorally, and pulmonary delivery.